Anti-ADA monoclonal antibody
Anti-ADA antibody for FACS & in-vivo assay
Go to ADA/ADA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T03661-Ab-1/ GM-Tg-hg-T03661-Ab-2 | Anti-Human ADA monoclonal antibody | Human |
GM-Tg-rg-T03661-Ab-1/ GM-Tg-rg-T03661-Ab-2 | Anti-Rat ADA monoclonal antibody | Rat |
GM-Tg-mg-T03661-Ab-1/ GM-Tg-mg-T03661-Ab-2 | Anti-Mouse ADA monoclonal antibody | Mouse |
GM-Tg-cynog-T03661-Ab-1/ GM-Tg-cynog-T03661-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ADA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T03661-Ab-1/ GM-Tg-felg-T03661-Ab-2 | Anti-Feline ADA monoclonal antibody | Feline |
GM-Tg-cang-T03661-Ab-1/ GM-Tg-cang-T03661-Ab-2 | Anti-Canine ADA monoclonal antibody | Canine |
GM-Tg-bovg-T03661-Ab-1/ GM-Tg-bovg-T03661-Ab-2 | Anti-Bovine ADA monoclonal antibody | Bovine |
GM-Tg-equg-T03661-Ab-1/ GM-Tg-equg-T03661-Ab-2 | Anti-Equine ADA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T03661-Ab-1/ GM-Tg-hg-T03661-Ab-2; GM-Tg-rg-T03661-Ab-1/ GM-Tg-rg-T03661-Ab-2; GM-Tg-mg-T03661-Ab-1/ GM-Tg-mg-T03661-Ab-2; GM-Tg-cynog-T03661-Ab-1/ GM-Tg-cynog-T03661-Ab-2; GM-Tg-felg-T03661-Ab-1/ GM-Tg-felg-T03661-Ab-2; GM-Tg-cang-T03661-Ab-1/ GM-Tg-cang-T03661-Ab-2; GM-Tg-bovg-T03661-Ab-1/ GM-Tg-bovg-T03661-Ab-2; GM-Tg-equg-T03661-Ab-1/ GM-Tg-equg-T03661-Ab-2 |
Products Name | Anti-ADA monoclonal antibody |
Format | mab |
Target Name | ADA |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-ADA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ADA VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMAP000384 | Human ADA Adenovirus particle |
ORF Viral Vector | pGMLP000474 | human ADA Lentivirus plasmid |
ORF Viral Vector | vGMLP000474 | human ADA Lentivirus particle |
ORF Viral Vector | pGMAP000384 | Human ADA Adenovirus plasmid |
ORF Viral Vector | pGMLPm001966 | mouse Ada Lentivirus plasmid |
ORF Viral Vector | vGMLPm001966 | mouse Ada Lentivirus particle |
Target information
Target ID | GM-T03661 |
Target Name | ADA |
Gene ID | 100,11486,24165,717897,477236,101090683,280712,100070773 |
Gene Symbol and Synonyms | ADA,ADA-like,ADA1 |
Uniprot Accession | P00813,Q920P6,P56658 |
Uniprot Entry Name | ADA_HUMAN,ADA_RAT,ADA_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000196839 |
Target Classification | N/A |
The target: ADA, gene name: ADA, also named as . This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine in the purine catabolic pathway. Various mutations have been described for this gene and have been linked to human diseases related to impaired immune function such as severe combined immunodeficiency disease (SCID) which is the result of a deficiency in the ADA enzyme. In ADA-deficient individuals there is a marked depletion of T, B, and NK lymphocytes, and consequently, a lack of both humoral and cellular immunity. Conversely, elevated levels of this enzyme are associated with congenital hemolytic anemia. [provided by RefSeq, Sep 2019].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.